Scholarlink

<p>Despite the documented presence of anti-phospholipid antibodies (aPL) and autoantibodies in certain cohorts of sickle cell disease (SCD) patients, the clinical risk factors associated with their development and subsequent complications remain inadequately elucidated. This study aims to investigate the seroprevalence of aPL, anti-cyclic citrullinated peptide antibody (anti-CCP) and anti-nuclear antibodies (ANA), along with their correlation with hematological, inflammatory markers and clinical findings in patients SCD during steady state phase. This cross-sectional study involved 92 SCD patients, employing an automated hematology autoanalyzer for complete blood count alongside evaluating of inflammatory markers. aPL (IgM and IgG) and anti-CCP were measured via enzyme-linked immunosorbent assay and ANA tested through indirect immunofluorescence assay. The study revealed a prevalence of 17.4% for aPL (IgG), 13% for aPL (IgM), 41.3% for ANA, and 15.2% for anti-CCP among SCD patients, where aPL (IgG) positive individuals showing lower inflammatory markers and significant associations with chronic leg ulcers and thrombosis history. There was a correlation between anti-CCP positivity and arthritis, while Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio (PLR), and Systemic Immune Inflammation Index showed negative associations with arthritis and a positive relationship between PLR and leg ulcers in SCD patients. The significant seroprevalence of aPL and autoantibodies in SCD patients suggests that integrating immunological, hematological and inflammatory markers could enhance clinical assessments and therapeutic strategies for SCD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Correlation of Anti-phospholipid Antibodies, Anti-cyclic Citrullinated Peptide Antibody, Anti-nuclear Antibodies with Hematological Inflammatory Markers and Clinical Manifestations in Sickle Cell Disease During Steady State Phase

  • 期刊论文

  • 发表日期：

    2025年6月30日

查看全文
  • Mohammed A. W. Almorish,
  • Amal S. Beshr,
  • Mohammed S. Beshr,
  • Ahmed M. E. Elkhalifa,
  • Abozer Y. Elderdery,
  • Fawaz O. Alenazy,
  • Muharib Alruwaili,
  • Ebtisam Bakhsh,
  • Hazim Abdullah Alotaibi,
  • Khaled Mohammed Al-Sayaghi,
  • Mohammed A. Hameed Albalawi,
  • Burhanudin Saha

摘要

Despite the documented presence of anti-phospholipid antibodies (aPL) and autoantibodies in certain cohorts of sickle cell disease (SCD) patients, the clinical risk factors associated with their development and subsequent complications remain inadequately elucidated. This study aims to investigate the seroprevalence of aPL, anti-cyclic citrullinated peptide antibody (anti-CCP) and anti-nuclear antibodies (ANA), along with their correlation with hematological, inflammatory markers and clinical findings in patients SCD during steady state phase. This cross-sectional study involved 92 SCD patients, employing an automated hematology autoanalyzer for complete blood count alongside evaluating of inflammatory markers. aPL (IgM and IgG) and anti-CCP were measured via enzyme-linked immunosorbent assay and ANA tested through indirect immunofluorescence assay. The study revealed a prevalence of 17.4% for aPL (IgG), 13% for aPL (IgM), 41.3% for ANA, and 15.2% for anti-CCP among SCD patients, where aPL (IgG) positive individuals showing lower inflammatory markers and significant associations with chronic leg ulcers and thrombosis history. There was a correlation between anti-CCP positivity and arthritis, while Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio (PLR), and Systemic Immune Inflammation Index showed negative associations with arthritis and a positive relationship between PLR and leg ulcers in SCD patients. The significant seroprevalence of aPL and autoantibodies in SCD patients suggests that integrating immunological, hematological and inflammatory markers could enhance clinical assessments and therapeutic strategies for SCD.